Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study

Introduction. Evidence from the metastatic setting suggests that replacing conventional doxorubicin with nonpegylated liposomal doxorubicin (NPLD) for early breast cancer may maintain efficacy whilst reducing long-term cardiotoxicity, an important consideration with many patients going on to receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Neville, Camburn, Teresa, Keary, Ian, Houghton, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913086/
https://www.ncbi.nlm.nih.gov/pubmed/24527216
http://dx.doi.org/10.1155/2014/984067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913086/
https://www.ncbi.nlm.nih.gov/pubmed/24527216
http://dx.doi.org/10.1155/2014/984067

Ejemplares similares